793 related articles for article (PubMed ID: 16763660)
1. Therapeutic potential of Toll-like receptor 9 activation.
Krieg AM
Nat Rev Drug Discov; 2006 Jun; 5(6):471-84. PubMed ID: 16763660
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists.
Vollmer J; Krieg AM
Adv Drug Deliv Rev; 2009 Mar; 61(3):195-204. PubMed ID: 19211030
[TBL] [Abstract][Full Text] [Related]
3. Antiinfective applications of toll-like receptor 9 agonists.
Krieg AM
Proc Am Thorac Soc; 2007 Jul; 4(3):289-94. PubMed ID: 17607015
[TBL] [Abstract][Full Text] [Related]
4. CpG oligodeoxynucleotides as TLR9 agonists: therapeutic application in allergy and asthma.
Gupta GK; Agrawal DK
BioDrugs; 2010 Aug; 24(4):225-35. PubMed ID: 20623989
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic applications of synthetic CpG oligodeoxynucleotides as TLR9 agonists for immune modulation.
Jurk M; Vollmer J
BioDrugs; 2007; 21(6):387-401. PubMed ID: 18020622
[TBL] [Abstract][Full Text] [Related]
6. Toll-like receptor 9 activation with CpG oligodeoxynucleotides for asthma therapy.
Kline JN; Krieg AM
Drug News Perspect; 2008 Oct; 21(8):434-9. PubMed ID: 19034349
[TBL] [Abstract][Full Text] [Related]
7. CpG oligodeoxynucleotide nanomedicines for the prophylaxis or treatment of cancers, infectious diseases, and allergies.
Hanagata N
Int J Nanomedicine; 2017; 12():515-531. PubMed ID: 28144136
[TBL] [Abstract][Full Text] [Related]
8. Impact of modifications of heterocyclic bases in CpG dinucleotides on their immune-modulatory activity.
Vollmer J; Weeratna RD; Jurk M; Davis HL; Schetter C; Wüllner M; Wader T; Liu M; Kritzler A; Krieg AM
J Leukoc Biol; 2004 Sep; 76(3):585-93. PubMed ID: 15218053
[TBL] [Abstract][Full Text] [Related]
9. CpG oligodeoxynucleotides as TLR9 agonists: therapeutic applications in cancer.
Murad YM; Clay TM
BioDrugs; 2009; 23(6):361-75. PubMed ID: 19894778
[TBL] [Abstract][Full Text] [Related]
10. Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides.
Krieg AM
Curr Oncol Rep; 2004 Mar; 6(2):88-95. PubMed ID: 14751085
[TBL] [Abstract][Full Text] [Related]
11. Toll-like receptor 9 agonists and combination therapies: strategies to modulate the tumour immune microenvironment for systemic anti-tumour immunity.
Dongye Z; Li J; Wu Y
Br J Cancer; 2022 Nov; 127(9):1584-1594. PubMed ID: 35902641
[TBL] [Abstract][Full Text] [Related]
12. Phosphorothioate-modified CpG oligodeoxynucleotide (CpG ODN) induces apoptosis of human hepatocellular carcinoma cells independent of TLR9.
Zhang Y; Lin A; Zhang C; Tian Z; Zhang J
Cancer Immunol Immunother; 2014 Apr; 63(4):357-67. PubMed ID: 24452201
[TBL] [Abstract][Full Text] [Related]
13. CpG still rocks! Update on an accidental drug.
Krieg AM
Nucleic Acid Ther; 2012 Apr; 22(2):77-89. PubMed ID: 22352814
[TBL] [Abstract][Full Text] [Related]
14. CpG oligodeoxynucleotide-based therapy of lymphoid malignancies.
Weiner GJ
Adv Drug Deliv Rev; 2009 Mar; 61(3):263-7. PubMed ID: 19168102
[TBL] [Abstract][Full Text] [Related]
15. Approaches to enhancing immune responses stimulated by CpG oligodeoxynucleotides.
Mutwiri G; van Drunen Littel-van den Hurk S; Babiuk LA
Adv Drug Deliv Rev; 2009 Mar; 61(3):226-32. PubMed ID: 19162103
[TBL] [Abstract][Full Text] [Related]
16. The immunobiology and clinical potential of immunostimulatory CpG oligodeoxynucleotides.
Weiner GJ
J Leukoc Biol; 2000 Oct; 68(4):455-63. PubMed ID: 11037965
[TBL] [Abstract][Full Text] [Related]
17. TLR9 agonists as adjuvants for prophylactic and therapeutic vaccines.
Daubenberger CA
Curr Opin Mol Ther; 2007 Feb; 9(1):45-52. PubMed ID: 17330401
[TBL] [Abstract][Full Text] [Related]
18. Progress in drug development of immunostimulatory CpG oligodeoxynucleotide ligands for TLR9.
Vollmer J
Expert Opin Biol Ther; 2005 May; 5(5):673-82. PubMed ID: 15934842
[TBL] [Abstract][Full Text] [Related]
19. Immunostimulatory Activities of CpG-Oligodeoxynucleotides in Teleosts: Toll-Like Receptors 9 and 21.
Lai CY; Yu GY; Luo Y; Xiang R; Chuang TH
Front Immunol; 2019; 10():179. PubMed ID: 30800129
[TBL] [Abstract][Full Text] [Related]
20. A threshold level of TLR9 mRNA predicts cellular responsiveness to CpG-ODN in haematological and non-haematological tumour cell lines.
Assaf A; Esteves H; Curnow SJ; Browning MJ
Cell Immunol; 2009; 259(1):90-9. PubMed ID: 19573862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
